# Pfizer says its blood-cancer treatment met the main goal of an ongoing late-stage study.

*biotech · news · 2026-04-29 · MarketScreener*

## Key points

- Pfizer's Elrexfio met the main goal in a late-stage study for multiple myeloma.
- The drug significantly extended progression-free survival compared to a standard drug combination.
- Elrexfio's safety profile in the trial was consistent with previous studies.
- Pfizer aims to expand Elrexfio's approval from heavily pretreated to earlier-line patients.
- Overall survival data from the trial is not yet mature and continues to be collected.

**Companies:** Pfizer
**Countries:** United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/pfizer-says-blood-cancer-treatment-meets-goal-in-late-stage-study-ce7f59d3d08cf024)

---

Canonical: https://newsio.io/n/fd85de7d-5111-416c-baf7-171b36c82a71/pfizer-says-its-blood-cancer-treatment-met-the-main-goal-of-an-ongoing-late-stag
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works